United Therapeutics (NSDQ:UTHR) said today that it stepped closer to completing its $216 million acquisition of SteadyMed (NSDQ:STDY) after terminating the the HSR Act waiting period. The merger combines two companies that were in court as recently as last November, fighting over patents covering treprostinil, the active ingredient in both companies’ lead products. In the deal, United Therapeutics will pay […]
Mergers & Acquisitions
CeQur acquires wearable insulin delivery device
CeQur said today that it acquired a wearable, on-demand insulin delivery system from Johnson & Johnson‘s (NYSE:JNJ) Calibra Medical for an undisclosed amount. The Calibra device is designed to dose rapid-acting, mealtime insulin for people with Type II diabetes. In a 278-person study, use of the Calibra device resulted in higher ease-of-use and patient satisfaction […]
Gerresheimer to acquire Sensile Medical and its drug-delivery tech
Updated 7/13 to include the deal’s financial details. Gerresheimer plans to acquire Swiss medical technology company Sensile Medical and its array of liquid drug delivery devices. The buyout is a perfect fit in Gerresheimer’s portfolio, the company explained, since it will boost Gerresheimer’s drug delivery offerings and add new digital and electronic capabilities into the mix. […]
Catalent expands early-phase development skills with $139m Juniper buyout
Catalent (NYSE:CTLT) said today that it inked a $139 million deal to acquire Juniper Pharmaceuticals (NSDQ:JNP) and its early-stage product development services. The company noted that its Juniper acquisition, set at $11.50 per share, will complement Catalent’s formulation development offerings, bioavailability solutions and clinical-scale oral dose manufacturing capabilities. “Juniper’s proven solutions and capabilities will further support […]
Novartis to spin out Alcon ophthalmic subsidiary
Novartis (NYSE:NVS) said today that it’s planning to spin its Alcon ophthalmology subsidiary into a publicly traded company after years of speculation that it wanted to sell the ill-starred division. The Swiss pharma giant said it intends to hold on to Alcon’s $4.6 billion ophthalmic pharmaceuticals business under the Novartis Innovative Medicines umbrella, continuing a […]
Sirtex accepts CDH acquisition offer, moves away from Varian
In the ongoing back-and-forth to acquire Sirtex Medical (ASX:SRX), it seems that Varian Medical‘s (NYSE:VAR) $1.2 billion bid just wasn’t enough. Varian said today that it heard from Sirtex that the company’s board couldn’t turn down the $1.41 billion unsolicited offer from China’s CDH Investments. The bid from CDH Investments came in at a 20% premium […]
Johnson & Johnson OKs $2B LifeScan sale to Platinum Equity
Johnson & Johnson (NYSE:JNJ) said today that it accepted a binding offer of more than $2 billion from private equity shop Platinum Equity for its LifeScan blood glucose monitoring business as it moves toward the exit in the diabetes market. The New Brunswick, N.J.-based healthcare conglomerate early last year announced a strategic review of its LifeScan, […]
Denali acquires F-star Gamma and its antibody tech to help drugs cross the blood-brain barrier
Privately-held biopharma F-star said today that its partner, Denali Therapeutics (NSDQ:DNLI), chose to exercise its option to buy F-Star Gamma in a deal valued at approximately $471 million. The two companies first inked a collaboration in August 2016 to develop antibody technologies that help drugs cross the blood-brain barrier. “When you give an antibody via IV […]
Varian stands on $1.28B offer for Sirtex
Varian Medical (NYSE:VAR) said today that it stands behind its initial $1.28 billion bid to acquire Sirtex Medical (ASX:SRX) in the wake of a $1.41 billion counter offer from China’s CDH Investments. The unsolicited bid from CDH Investments came in at a 20% premium on Varian’s A$28-per-share offer, prompting Sirtex to reconsider a merger that already […]
TapImmune adds cell therapy to peptide vaccine portfolio with Marker Therapeutics merger
TapImmune (NSDQ:TPIV) expanded its immuno-oncology capabilities today with a deal to acquire Marker Therapeutics and its clinical-stage, multi-antigen T cell therapy platform. Details regarding merger-related financing were not disclosed, but TapImmune said it is in talks with a syndicate of institutional investors to fund the company until 2020. “I believe that the new therapies we are […]